Literature DB >> 15800566

Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication.

Jenny-Kay Sharpe1, Nuala M Byrne, Terry J Stedman, Andrew P Hills.   

Abstract

Resting energy expenditure (REE) is lower than predicted in persons taking atypical antipsychotic medication, and weight management is a significant clinical challenge for some of them. However, to date there have been no published guidelines to assist clinicians in choosing appropriate prediction equations to estimate energy expenditure in persons taking atypical antipsychotic medications. The objectives of this study were to measure REE in a group of men taking the atypical antipsychotic clozapine and to determine whether REE can be accurately predicted for this population using previously published regression equations. REE was measured using indirect calorimetry via a ventilated hood on eight men who had completed at least 6 months of treatment with clozapine. Comparisons between measured REE and predicted REE using five different equations were undertaken. The commonly-used Harris-Benedict and Schofield equations systematically overestimated REE. Predictions of REE from other equations were too variable for clinical use. When estimating energy requirements as part of a weight-management program in men who have been taking clozapine for 6 months, predictions of REE from the equations of Harris-Benedict and Schofield should be reduced by 280 kcal/day.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800566     DOI: 10.1016/j.jada.2005.01.005

Source DB:  PubMed          Journal:  J Am Diet Assoc        ISSN: 0002-8223


  9 in total

Review 1.  The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.

Authors:  C Cuerda; C Velasco; J Merchán-Naranjo; P García-Peris; C Arango
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

Review 2.  Addressing cardiometabolic risk during treatment with antipsychotic medications.

Authors:  Jonathan M Amiel; Christina V Mangurian; Rohan Ganguli; John W Newcomer
Journal:  Curr Opin Psychiatry       Date:  2008-11       Impact factor: 4.741

Review 3.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Atypical antipsychotics and effects on feeding: from mice to men.

Authors:  Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-01       Impact factor: 4.530

Review 5.  The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.

Authors:  Meng He; Chao Deng; Xu-Feng Huang
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

6.  Comparison of predictive equations for resting energy expenditure among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Tetsu Tomita; Hanako Furukori; Kazutoshi Kubo; Taku Nakagami; Sunao Kaneko
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-28       Impact factor: 2.570

7.  Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.

Authors:  Zachary Freyberg; Despoina Aslanoglou; Ripal Shah; Jacob S Ballon
Journal:  Front Neurosci       Date:  2017-07-28       Impact factor: 4.677

8.  Effects of risperidone on energy balance in female C57BL/6J mice.

Authors:  Xingsheng Li; Maria S Johnson; Daniel L Smith; Yan Li; Robert A Kesterson; David B Allison; Tim R Nagy
Journal:  Obesity (Silver Spring)       Date:  2013-05-29       Impact factor: 5.002

Review 9.  Eating disorders in schizophrenia: implications for research and management.

Authors:  Youssef Kouidrat; Ali Amad; Jean-Daniel Lalau; Gwenole Loas
Journal:  Schizophr Res Treatment       Date:  2014-11-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.